NASDAQ | ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology.
The fund is non-diversified.
Top 20 Holdings
Asset | Name | Sector | Industry | Weight |
---|---|---|---|---|
BBIO | BridgeBio Pharma Inc | Healthcare | Biotechnology | 5.31% |
RVMD | Revolution Medicines Inc | Healthcare | Biotechnology | 5.25% |
RHHBY | Roche Holding Ltd ADR | Healthcare | Drug Manufacturers - General | 4.87% |
NOVN | Novartis AG | Healthcare | Drug Manufacturers - General | 4.59% |
MRUS | Merus BV | Healthcare | Biotechnology | 4.42% |
AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 4.41% |
GMAB | Genmab AS | Healthcare | Biotechnology | 4.11% |
LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 3.87% |
ACLX | Arcellx Inc | Healthcare | Biotechnology | 3.15% |
BGNE | BeiGene Ltd | Healthcare | Biotechnology | 3.14% |
BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 3.12% |
EXEL | Exelixis Inc | Healthcare | Biotechnology | 3.09% |
SMMT | Summit Therapeutics PLC | Healthcare | Biotechnology | 3.07% |
NUVL | Nuvalent Inc | Healthcare | Biotechnology | 3.03% |
IMGN | ImmunoGen Inc | Healthcare | Biotechnology | 3.00% |
ABBV | AbbVie Inc | Healthcare | Drug Manufacturers - General | 2.88% |
ZLAB | Zai Lab Ltd | Healthcare | Biotechnology | 2.84% |
LEGN | Legend Biotech Corp | Healthcare | Biotechnology | 2.61% |
AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 2.31% |
MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 2.26% |